Bluebird Bio to Be Acquired by Carlyle Group, SK Capital
Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.
BioPharma Dive21h
Bluebird, at risk of default, agrees to take-private deal
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
Birkenstock Adds Winter Assortment, But The Stock Remains Too Expensive
Birkenstock Holding plc sees 19% YOY growth, but market flags deceleration & high valuation risks. Click for insights on BIRK ...